Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of L-aspartic acid beta-hydroxamate in preparation of drugs for inhibiting choroidal neovascularization, and choroidal neovascularization treatment method

A hydroxamate and aspartic acid technology, applied in drug delivery, pharmaceutical formulation, drug combination, etc., can solve the problems of retinal and choroidal atrophy, side effects, intraocular infection, etc., and achieve the effect of inhibiting choroidal neovascularization

Inactive Publication Date: 2019-05-28
WENZHOU MEDICAL UNIV
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, anti-VEGF antibodies are widely used clinically (including bevacizumab, ranibizumab, etc.), but repeated intravitreal injections of anti-VEGF antibodies will produce serious side effects: including retinal and choroidal atrophy caused by long-term use of VEGF antibodies; repeated vitreous cavity Injections induce retinal detachment, intraocular infection, urgent need for better treatment options

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of L-aspartic acid beta-hydroxamate in preparation of drugs for inhibiting choroidal neovascularization, and choroidal neovascularization treatment method
  • Application of L-aspartic acid beta-hydroxamate in preparation of drugs for inhibiting choroidal neovascularization, and choroidal neovascularization treatment method
  • Application of L-aspartic acid beta-hydroxamate in preparation of drugs for inhibiting choroidal neovascularization, and choroidal neovascularization treatment method

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0016] experimental method:

[0017] Using the animal model of exAMD, in C57 / B6 mice, using Krypton red laser (0.05 s interval, 0.07 s duration, and 240 mW power), do fundus irradiation to create CNV mouse model. Serine racemase competitive inhibitor, L-Aspartic acid β-hydroxamate (l-Aspartic acid β-hydroxamate) was injected intravenously at a dose of 6 mg / kg on the day before laser and 3 mg / kg on the third day after laser. -hydroxamate, L-ABH). On day 7 after laser injury, choroid / retinal pigment epithelial cells (RPEs) were spread and stained with Alexa Fluor 594-conjugated isolectin GS-IB4 to analyze CNV volume. And using primary RPEs in vitro, study the inhibitory effect of L-ABH on the production of VEGF and MCP-1 induced by TNFα in RPEs. And use RPEs and macrophage co-culture, research L-ABH pretreatment RPEs, inhibit the migration of macrophages.

[0018] Intravenous injection of L-ABH inhibits laser-induced choroidal neovascularization as a result of figure 1 shown...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of L-aspartic acid beta-hydroxamate in preparation of drugs for inhibiting choroidal neovascularization, and a choroidal neovascularization treatment method. Through intravenous injection of the L-aspartic acid beta-hydroxamate, secretion of VEGF and MCP-1 by TNF alpha-induced RPE is inhibited, so that the choroidal neovascularization is suppressed, and seriousside effects, such as retinal and choroidal atrophy, retinal detachment and intraocular infection, caused by repeated intravitreal injection of anti-VEGF antibodies are avoided.

Description

technical field [0001] The invention specifically relates to the technical field of choroidal neovascularization, in particular to the application and method of L-aspartic acid β-hydroxamate in the preparation of drugs for inhibiting choroidal neovascularization. Background technique [0002] Choroidal neovascularization (CNV) is an important pathological feature of exudative age-related macular degeneration (exAMD) main cause of loss. At present, anti-VEGF antibodies are widely used clinically (including bevacizumab, ranibizumab, etc.), but repeated intravitreal injections of anti-VEGF antibodies will produce serious side effects: including retinal and choroidal atrophy caused by long-term use of VEGF antibodies; repeated vitreous cavity Injections induce retinal detachment, intraocular infection, and better treatment options are urgently needed. Contents of the invention [0003] In order to avoid the defects of the prior art, the present invention provides an applicat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/198A61P27/02
CPCA61K31/198A61P27/02A61K9/0019
Inventor 吴圣洲吴梦娟刘依美
Owner WENZHOU MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com